Nexvel Biotech to Make Its Debut at Cosmobeauté Vietnam 2026

Nexvel Biotech, a specialized company in aesthetic medicine and cosmeceuticals, will make its first appearance at Cosmobeauté Vietnam 2026, signaling the company's official entry into the Southeast Asian market. This exhibition represents a significant milestone in Nexvel Biotech's global expansion strategy, serving as the first official platform to introduce its proprietary hyaluronic acid (HA)-based technologies and medical aesthetic expertise to Southeast Asia. At the exhibition, Nexvel Biotech will showcase its flagship skin booster and cosmeceutical product portfolio developed through years of research and innovation. The company aims to establish new business opportunities with buyers, distributors, and industry professionals across the rapidly growing Southeast Asian beauty market. Demand for scientifically proven, technology-driven cosmeceutical solutions continues to rise throughout Southeast Asia, as consumers increasingly seek products that deliver measurable results beyond conventional skincare benefits. Leveraging its extensive expertise in HA research and proprietary technology platforms, Nexvel Biotech is well-positioned to demonstrate its competitive strengths to international partners. A company representative stated, "Cosmobeauté Vietnam 2026 is a meaningful opportunity for Nexvel Biotech to take its first step into the Southeast Asian market. Through this exhibition, we aim to build strategic partnerships, expand our global network, and strengthen our position as a leading provider of aesthetic and cosmeceutical solutions." The exhibition is expected to serve as a launchpad for Nexvel Biotech's Southeast Asian growth strategy and a key milestone in bringing its innovative technologies to new international markets.  

2026.07.23

Nexvel Biotech Showcases Its Medical Aesthetics Expertise at Vietbeauty Cosmobeauté Vietnam 2026, Accelerating Global ...

Nexvel Biotech Showcases Its Medical Aesthetics Expertise at Vietbeauty & Cosmobeauté Vietnam 2026, Accelerating Global Market Expansion   Nexvel Biotech, a leading medical aesthetics company, successfully participated in Vietbeauty & Cosmobeauté Vietnam 2026, held from July 23 to 25 at the Saigon Exhibition and Convention Center (SECC) in Ho Chi Minh City, Vietnam. Through the exhibition, the company strengthened its global presence and further expanded its business opportunities across the ASEAN region.   Vietbeauty & Cosmobeauté is one of Southeast Asia's largest B2B beauty exhibitions, bringing together global buyers, distributors, medical professionals, and beauty industry leaders every year. As the beauty industry increasingly converges with medical aesthetics and biotechnology, the exhibition has become an important platform for companies with advanced scientific and clinical expertise.   At the exhibition, Nexvel Biotech presented its flagship medical aesthetics portfolio, including Aeshilo™, Amethea PLLA™, Amethea PN™, Amethea SA™, and Amethea NAD™. The company's next-generation hyaluronic acid (HA)-based skin booster and PLLA-based collagen regeneration solutions attracted significant attention from international buyers seeking innovative, clinically driven aesthetic products.   Vietnam's medical aesthetics industry continues to grow rapidly, while the skin booster segment remains in its early stage of development. This presents promising opportunities for advanced technologies and premium treatment solutions. During the exhibition, Nexvel Biotech confirmed the strong market potential for Korean-made skin boosters and experienced growing demand for scientifically developed aesthetic products.   Throughout the three-day exhibition, the company held productive business meetings with buyers from Vietnam, India, Indonesia, the Philippines, the Middle East, and other international markets. Visitors expressed strong interest in Nexvel Biotech's differentiated technologies, manufacturing capabilities, product quality, and clinical development expertise, leading to active discussions on new distribution partnerships and market expansion.   In addition to its medical device portfolio, Nexvel Biotech also introduced DU2LAB, its premium cosmeceutical skincare brand developed from the company's skin booster technology. Built upon years of expertise in medical aesthetic research and development, DU2LAB demonstrated how advanced medical technologies can be translated into high-performance daily skincare solutions. This unique brand story resonated strongly with international buyers and highlighted a new direction where medical aesthetics and cosmetics converge.   A company representative commented, "This exhibition confirmed the growing global interest in Korean skin booster technology and medical aesthetics. We were especially encouraged by the positive response to Nexvel Biotech's R&D capabilities and technological expertise, which further strengthened our confidence in expanding into new international markets."   The representative added, "The valuable market insights and buyer feedback obtained during the exhibition will serve as an important foundation for our localization strategies and future global partnerships. Moving forward, we will continue to invest in research and innovation while expanding our international network to deliver advanced medical aesthetic solutions to customers worldwide."   With the global medical aesthetics market continuing to grow alongside increasing demand for skin rejuvenation, minimally invasive treatments, and science-based skincare, Nexvel Biotech is committed to strengthening its leadership in skin boosters and dermal fillers while expanding its integrated medical aesthetics and cosmeceutical business. The company aims to further establish the global reputation of Korean medical aesthetic technology through continuous innovation and long-term partnerships.  

2026.07.24

DU2LAB Vietbeauty Cosmobeauté Vietnam 2026

DU2LAB Showcases Global Competitiveness at Vietbeauty & Cosmobeauté Vietnam 2026 Premium cosmeceutical brand DU2LAB successfully participated in Vietbeauty & Cosmobeauté Vietnam 2026, one of Southeast Asia's largest beauty trade exhibitions, held at the Saigon Exhibition and Convention Center (SECC) in Ho Chi Minh City. The exhibition marked another important milestone in the brand's global expansion strategy.   During the three-day exhibition, DU2LAB conducted 32 business meetings with international buyers, identifying 17 companies as high-potential (Grade A) partners. Distributors and beauty professionals from Vietnam and neighboring Southeast Asian markets expressed strong interest in the brand's technology and product portfolio, leading to active discussions on future business partnerships.   A major highlight of the exhibition was DU2LAB's proprietary 3-Step Patented Technology, which drew significant attention for its innovative approach to premium skincare. Designed to support healthy-looking skin through science-driven formulation and efficacy-focused development, the products received highly positive feedback from buyers seeking advanced, high-performance skincare solutions.   As demand for premium skincare and functional cosmetics continues to grow across Southeast Asia, global buyers are increasingly looking beyond the K-Beauty trend to brands that offer proven technology, product efficacy, and long-term credibility. With its patented innovations and differentiated product development capabilities, DU2LAB demonstrated its strong potential to become a trusted global skincare brand. A DU2LAB representative commented, "This exhibition allowed us to confirm the growing interest in our brand not only in Vietnam but throughout Southeast Asia. We will continue expanding our local partnerships while strengthening our competitiveness through continuous research, innovation, and product development." Building on the success of Vietbeauty & Cosmobeauté Vietnam 2026, DU2LAB plans to further expand its global distribution network and reinforce its position as a premium science-driven cosmeceutical brand in international markets.

2026.07.24

[Interview] Park Joong-woo, Executive Director at Nexbell Biotech: The Era of Skin Boosters Is Here

Nexbel Biotech Challenges Korea's First Non-Crosslinked HA Medical Device...Aiming for Commercialization by 2028 Launched the cosmetic brand 'Amethea' in April 2026.Recruited overseas sales expert Executive Director Hye-jung Kwon, exporting cosmetics to 10 countries.   "We have moved beyond the era of filling facial volume to an era of improving skin health and skin condition itself." Market Economy met Jung-woo Park, Managing Director at Nexbel Biotech, who expressed confidence in developing Korea's first non-crosslinked Hyaluronic Acid (HA) skin booster. We discussed the evolving skin booster market, the company's technological edge, and its future business strategies. The center of gravity in the aesthetic medical device market is rapidly shifting from dermal fillers to skin boosters. While filler procedures for volume enhancement were mainstream in the past, demand for skin boosters—which improve intrinsic skin health such as texture, tone, elasticity, and radiance—has grown significantly. Amid these market dynamics, Nexbel Biotech has recently raised industry interest by challenging the development of Korea's first non-crosslinked HA skin booster medical device. Leveraging over 20 years of field experience in distributing medical devices such as fillers and skin boosters, Nexbel Biotech has engaged in R&D and is currently conducting clinical trials for its medical device.   Q: Could you introduce Nexbel Biotech? A: "Nexbel Biotech is a biotechnology company that researches, develops, and manufactures medical devices in the aesthetic dermatology field. We operate manufacturing facilities in Cheongju, Chungcheongbuk-do, handling everything directly from R&D to manufacturing and sales. We have secured ISO 13485 (Medical Devices Quality Management System) and ISO 22716 (Cosmetics GMP) certifications. Above all, our competitive edge lies in the hands-on experience and market insights gained over 20 years of distributing fillers and skin boosters. Knowing firsthand what medical professionals actually need in the field significantly empowers our current R&D efforts."   Q: Why are skin boosters attracting so much attention recently? A: "In the past, filler procedures designed to add facial volume for a youthful look were dominant. Post-pandemic, however, consumers seeking natural beauty have increased drastically. Demand is shifting from simply 'filling' the face to improving core skin conditions—such as skin texture, tone, elasticity, and radiance. From a practitioner’s perspective, skin boosters are preferred due to shorter procedure times and relatively quick recovery. In fact, while the global filler market grows at an average annual rate of around 8%, the skin booster market is projected to maintain double-digit annual growth."   Q: How do skin boosters differ from general cosmetics? A: "Many consumers consider cosmetics and skin boosters to be similar, but they are fundamentally different. Cosmetics are topical products applied to the surface of the skin. Skin boosters, on the other hand, are sterilized medical devices delivered directly into the dermal layer to improve the skin's microenvironment. Designed to act directly within the skin, their manufacturing process and quality control standards are incomparably more rigorous."   Q: What are the key features of the product currently under development? A: "We are developing 'Aeshilo,' a non-crosslinked HA skin booster utilizing our proprietary AHCT (AI HA Compound Technology). While conventional products mostly use crosslinking agents, our product features a non-crosslinked formulation. By combining high-molecular-weight and low-molecular-weight hyaluronic acid, it is engineered to simultaneously deliver hydration and skin condition improvement. Notably, being the first in Korea to undertake clinical trials for a non-crosslinked HA skin booster medical device holds great significance for us."   Q: Why do you place so much emphasis on conducting clinical trials? A: "Because objective data matters far more than flashy marketing. Although the skin booster market has expanded rapidly, few products have thoroughly validated their safety and efficacy through clinical data. Successfully completing our ongoing clinical trials will allow us to establish a new benchmark in Korea's non-crosslinked HA skin booster sector."   Q: What is the timeline for commercialization? A: "We are currently conducting clinical trials. Our goal is to complete the clinical trials in the second half of next year, go through the regulatory approval process, and achieve commercialization by the first quarter of 2028."   Q: We understand that you are pursuing a cosmetics business ahead of the medical device launch. A: "Alongside our medical device clinical trials, we are rolling out our cosmetic brand 'Amethea.' We began sales in April this year and received very positive responses from international buyers at trade shows such as Beauty Eurasia in Istanbul and CosmoBeauty Seoul. We are currently exporting to around 10 countries and plan to introduce a wider product lineup sequentially."   Q: How are you preparing for international markets? A: "Global interest in K-Beauty and K-Medical continues to rise. Because there is no dominant global player in the skin booster market yet, we see significant opportunities. We recently brought on Executive Director Hye-jung Kwon, an overseas sales specialist, to expand our global network, actively focusing on the Middle East and Southeast Asia. Our strategy is to pioneer markets with cosmetics first and later expand with our medical devices."   Q: How do you foresee the future of the aesthetic medical market? A: "The filler market will not disappear, but the main center of gravity is undeniably shifting toward skin boosters. Major global filler manufacturers and pharmaceutical firms are rushing into skin booster development. Moving forward, aesthetic procedures that maintain healthy skin will expand much faster than procedures that drastically alter facial features."   Q: Do you have any final remarks? A: "Since the initial development stage, Nexbel Biotech has operated on the principle of 'creating products backed by data.' Technology can only earn market trust through objective validation. Our goal is to successfully complete the ongoing non-crosslinked HA skin booster clinical trials, enhance the competitiveness of Korea's medical aesthetic industry, and grow into a globally trusted K-Medical brand."    

2026.07.16

As the Boundaries Between Beauty and Medical Aesthetics Continue to Blur: The Potential of Du2LAB Discovered at Cosmobe...

As the Boundaries Between Beauty and Medical Aesthetics Continue to Blur: The Potential of Du2LAB Discovered at Cosmobeauty Seoul 2026 After covering global beauty exhibitions for the past three years, one trend has become increasingly clear: "The line between beauty brands and medical brands is disappearing." While the beauty industry was once driven primarily by packaging, branding, and emotional appeal, today's global market is paying closer attention to brands backed by clinical credibility, scientific research, and technologies developed through dermatology, plastic surgery, and medical aesthetics. Cosmobeauty Seoul 2026, held this past May at COEX in Seoul, provided a clear reflection of this shift. Although ingredients such as PDRN, exosomes, peptides, and collagen continued to dominate industry conversations, overseas buyers were focusing on something deeper. Their primary interest was no longer the ingredient itself, but rather the technology behind it—the research, development, and manufacturing capabilities that support product performance. This signals a broader transformation of the global beauty market: a shift from an ingredient-driven industry to a technology-driven one. From this perspective, one of the most impressive brands observed during the exhibition was Du2LAB.   Du2LAB's strength extends beyond conventional skincare branding. Its greatest asset lies in the medical aesthetic technologies supporting the brand. Its parent company, Nexvel Biotech, has continuously invested in research and development within the fields of hyaluronic acid-based skin boosters and dermal fillers. At Cosmobeauty Seoul 2026, the company showcased a diverse portfolio of aesthetic solutions, including the Dual HA Skin Booster, Roseeplla Filler, and Amethea Skin Booster series. Among them, the Dual HA technology deserves particular attention. By combining high- and low-molecular-weight hyaluronic acid, the technology aligns perfectly with the growing global focus on "Skin Quality. " While the filler market once centered primarily on volume enhancement, demand has increasingly shifted toward improving overall skin condition, including texture, elasticity, radiance, and long-term hydration. Buyers from Europe and the Middle East have shown particularly strong interest in the rapidly expanding skin booster category, a trend that was clearly evident throughout Cosmobeauty Seoul 2026. What makes Du2LAB even more noteworthy is its ability to translate medical aesthetic expertise into consumer-focused cosmeceutical products.   Today's global consumers are influenced less by the message that an ingredient is included and more by how that ingredient is delivered and supported by technology. Leveraging years of experience in hyaluronic acid research, Du2LAB has developed proprietary platforms such as Dual HA Delivery, Lacto-Exosome, and GHK-Cu Peptide Complex, creating a brand story that is difficult for conventional skincare companies to replicate. This represents a competitive advantage rooted in technology rather than marketing. Global demand for technology-driven cosmeceutical brands continues to rise, particularly across the United States, Japan, and the Middle East, where consumers increasingly seek products supported by medical expertise and clinical credibility. Against this backdrop, Du2LAB appears well-positioned to benefit from these evolving market dynamics.   Cosmobeauty Seoul 2026 demonstrated that K-Beauty is entering another stage of evolution. The industry is now evaluating brands based on technology and R&D capabilities rather than marketing claims alone. At the center of this transformation are brands capable of bridging the worlds of medical aesthetics and cosmeceuticals. Among the many exhibitors present, Du2LAB stood out for precisely this reason. A brand that begins with technology and transforms it into meaningful products. As the global cosmeceutical market continues to evolve, Du2LAB is undoubtedly a name worth watching.

2026.05.28

[Du2LAB] Emerges as a Standout Brand at Cosmobeauty Seoul 2026

In the Era of Choosing Technology Over Ingredients, Du2LAB Emerges as a Standout Brand at Cosmobeauty Seoul 2026 Technology has become the true competitive edge in beauty. Held at COEX in Seoul from May 27 to 29, Cosmobeauty Seoul 2026 was more than just a beauty exhibition — it served as a key platform to observe the present and future of the K-beauty industry. With major Korean and international beauty brands, ingredient suppliers, manufacturers, and global buyers participating, the event once again demonstrated the strong worldwide demand for K-beauty. One of the most notable shifts this year was that both consumers and buyers are no longer responding only to trendy ingredients or marketing buzzwords. While ingredients such as PDRN, exosomes, and peptides remained popular, conversations on the exhibition floor increasingly focused on how ingredients are delivered to the skin and what scientific and technological foundation supports the product. In other words, the market is moving from an ingredient-driven competition to a technology-driven competition. Amid this shift, one brand that stood out prominently to this reporter was Du2LAB.     While many brands highlighted trendy ingredients, Du2LAB differentiated itself by emphasizing its delivery platform technologies rather than ingredients alone. The brand introduced three proprietary technologies: Dual HA Delivery, Lacto-Exosome, and GHK-Cu Peptide Complex. What made Du2LAB particularly compelling was that these technologies were not presented as mere cosmetic concepts. The company’s technological foundation stems from its experience in manufacturing hyaluronic acid fillers and skin boosters used in medical clinics. This aligns closely with the core values currently driving the global cosmeceutical market: scientific credibility and tangible efficacy. Overseas buyers responded strongly to this positioning. Throughout the exhibition, buyers from key Asian markets including Kazakhstan and Japan visited the Du2LAB booth for in-depth consultations regarding its technologies and product lineup. In fast-growing cosmeceutical markets, interest was especially high in the brand’s scientific background and validation process — areas where Du2LAB provided clear and convincing answers.     Another important takeaway from this year’s exhibition is that the standards for K-beauty are rising rapidly. In the past, attractive packaging and competitive pricing were often enough to succeed globally. Today, however, brands are evaluated comprehensively on patented technologies, research data, ingredient differentiation, and manufacturing expertise. From that perspective, Du2LAB feels less like a conventional skincare brand and more like a technology-based cosmeceutical company. While its mainstream consumer recognition may still trail some mega-brands, its growth potential appears especially strong when viewed through the lens of global buyers and industry professionals. Cosmobeauty Seoul 2026 clearly showed that K-beauty is entering another phase of evolution. And at the center of that transformation are brands that are not merely selling products, but building new markets through science, technology, and research. Among them, Du2LAB is undoubtedly a name worth watching in the global cosmeceutical market.

2026.05.27

[Du2LAB] Demonstrates Global Market Potential at BEAUTYISTANBUL 2026

Du2LAB Demonstrates Global Market Potential at BEAUTYISTANBUL 2026 K-Beauty Brand Captivates International Buyers with a Strong Combination of Technology, Sensory Appeal, and Premium Branding South Korean cosmeceutical brand Du2LAB successfully demonstrated its growing competitiveness in the global beauty market through its participation in BEAUTYISTANBUL 2026, held in Istanbul, Türkiye. Recognized as one of the key beauty exhibitions connecting Europe, the Middle East, and Africa, BEAUTYISTANBUL attracts beauty brands, distributors, and buyers from around the world each year. Amid the continued global rise of K-beauty, overseas buyers are increasingly focusing on Korean brands that successfully combine functional skincare innovation with sophisticated brand identity and emotional appeal. At this year’s exhibition, Du2LAB introduced its product portfolio centered around the brand’s signature frankincense-inspired fragrance, proprietary 3-Step patented technology, and premium package design. During the event, the company held active business meetings with more than 50 global buyers from over 25 countries, including Türkiye, Iraq, Egypt, Saudi Arabia, the UAE, Romania, Moldova, Malaysia, and the United Kingdom. One of the most notable achievements was the complete sell-out of showcased products within just two days of the exhibition. Industry observers viewed this not merely as strong exhibition traffic, but as clear evidence of immediate purchasing demand and strong market responsiveness toward the brand. Du2LAB’s sophisticated brand identity and differentiated product experience received particularly positive feedback from international buyers. Its frankincense-based signature scent drew significant attention from buyers in the Middle East and Europe, with many evaluating the products as offering a “premium beauty experience” that extends beyond skincare functionality to emotional and sensorial satisfaction. The company’s proprietary 3-Step patented technology also attracted considerable attention from industry professionals and overseas distributors. Designed to enhance ingredient absorption and optimize active ingredient delivery, the technology aligns closely with the rapidly growing global demand for high-performance functional skincare solutions. Industry analysts note that the global beauty market is increasingly shifting beyond basic moisturizing and brightening products toward advanced skincare solutions focused on skin condition improvement and ingredient delivery efficiency. In addition, Du2LAB’s premium package design was regarded as another key factor strengthening the brand’s competitiveness. Industry experts point out that today’s global consumers increasingly evaluate not only product efficacy, but also brand storytelling, design sophistication, and overall user experience—areas where Du2LAB appears to have established a strong competitive advantage. Several international buyers reportedly expressed strong interest in securing exclusive distribution partnerships during the exhibition. This level of interest is being interpreted as more than simple export inquiries, reflecting growing confidence in the brand’s long-term market scalability and business potential. A beauty industry official commented, “As product functionality alone is no longer enough to differentiate brands in the global market, companies that successfully integrate technology, emotional branding, and design competitiveness are gaining greater attention. Du2LAB represents a compelling example of a K-cosmetic brand that has effectively balanced functional innovation with a premium brand image.” A representative from Du2LAB stated, “Through BEAUTYISTANBUL 2026, we were able to directly confirm the global potential of our brand and the strong market response from international buyers. Moving forward, we plan to continue expanding the global competitiveness of K-beauty through ongoing R&D and differentiated branding strategies.” Meanwhile, the global cosmeceutical market continues to experience steady growth alongside increasing consumer demand for wellness-oriented skincare and premium beauty experiences. Industry experts expect Korean companies that successfully strengthen both technological innovation and brand experience to further expand their presence in overseas markets.

2026.05.07

2026 Cosmobeauty Seoul

Nexvel Biotech Introduces Medical Technology-Based Cosmetic Brand ‘Du2LAB’ at COSMOBEAUTY SEOUL 2026 Integrated Manufacturing, R&D, Export, and Distribution System Strengthens Confidence in Functional Cosmeceutical Brand South Korean medical and bio company Nexvel Biotech is set to officially enter the beauty market through its cosmetic brand Du2LAB. The brand will make its domestic debut at COSMOBEAUTY SEOUL 2026, drawing industry attention as a functional cosmetic brand developed with medical-device-based technology. The global beauty industry is rapidly evolving beyond conventional skincare products toward the growing “cosmeceutical” sector, where consumers increasingly prioritize skin improvement, functionality, and safety. As purchasing standards shift from simple brand image to technological reliability, ingredient stability, and manufacturing credibility, companies with medical technology expertise are emerging as new leaders in the beauty industry. Against this backdrop, Nexvel Biotech has strengthened its competitiveness by establishing an integrated business structure that directly manages research and development (R&D), manufacturing, quality control, exports, and global distribution based on its patented medical device technologies. Industry experts note that companies capable of independently overseeing the entire process—from product development to global distribution—remain relatively rare in the Korean beauty industry. Building on its accumulated expertise in the medical aesthetics sector, Nexvel Biotech has expanded its business portfolio by launching Du2LAB, a functional cosmeceutical brand rooted in medical technology. The brand is being recognized for its differentiated competitiveness, as the company’s skin science-based technologies and quality management systems originally developed for medical devices have been applied to cosmetic product development. Industry analysts point out that modern consumers increasingly prefer products that deliver visible skin condition improvement and tangible user satisfaction rather than products that simply appear visually appealing. In particular, the medical cosmeceutical sector—driven by high-performance ingredients, advanced absorption technology, and product safety—is considered one of the fastest-growing segments within the global beauty market. Reflecting these market trends, Du2LAB plans to present a brand strategy that combines emotional brand experience with medically driven functionality. The products are reportedly formulated using Nexvel Biotech’s proprietary technologies, focusing on enhanced absorption efficiency, optimized active ingredient delivery, and product safety. In addition, Nexvel Biotech’s established global distribution network is regarded as another key factor supporting Du2LAB’s growth potential. Leveraging the international partnerships and export channels built through its medical device and medical aesthetics businesses, the company is expanding into the cosmetics sector while continuously strengthening connections with global buyers through participation in international exhibitions. Industry observers believe that Du2LAB’s credibility will be further enhanced by the fact that it is backed by a company operating its own manufacturing infrastructure and quality management systems. In the global beauty market, brands with in-house production capabilities are increasingly gaining competitive advantages as consumers place greater emphasis on quality stability and manufacturing transparency. A beauty industry expert commented, “The cosmetics industry has entered an era where emotional branding alone is no longer enough to remain competitive. Companies capable of combining technological expertise, manufacturing reliability, and global distribution competitiveness are expected to lead the market moving forward. Du2LAB represents a noteworthy example of a brand successfully integrating medical-based functionality with a premium branding strategy.” A representative from Nexvel Biotech stated, “COSMOBEAUTY SEOUL 2026 will serve as a meaningful opportunity to introduce Du2LAB to domestic consumers and buyers for the first time. We plan to continue strengthening the brand’s competitiveness through differentiated product development based on medical technology and expanded global market presence.” Meanwhile, COSMOBEAUTY SEOUL 2026 is recognized as one of Korea’s leading beauty industry exhibitions, attracting domestic and international beauty brands and buyers while serving as a key platform for showcasing the latest K-beauty technologies and global trends.  

2026.05.19

2026 Beauty Istanbul Exhibition

Nexvel Biotech Accelerates Global Expansion Evolving into a Total Medical Aesthetics Company Integrating Manufacturing, Distribution, and Cosmetics Based on Patented Medical Device Technology South Korean medical and bio company Nexvel Biotech is drawing industry attention as it officially begins expanding into global markets following its participation in BEAUTYISTANBUL 2026. Built upon patented medical device technologies, the company has established a business structure that directly manages the entire process from manufacturing to export and distribution. More recently, Nexvel Biotech has successfully launched a technology-based cosmetic brand, further strengthening its competitiveness in the medical aesthetics sector. Leveraging its accumulated expertise in medical devices and aesthetic medicine, Nexvel Biotech has developed an integrated business system that organically connects in-house research and development (R&D), manufacturing, and global distribution networks. Industry analysts note that the company differentiates itself by going beyond conventional OEM and ODM production, directly overseeing product planning, technology development, manufacturing, quality control, and overseas distribution. Industry experts point out that the global medical aesthetics market is increasingly shifting away from simple price competition toward a structure that prioritizes technological reliability, product safety, and brand competitiveness. In response to this trend, Nexvel Biotech has strengthened its global market competitiveness by enhancing product quality through its proprietary patented technologies. Through its participation in BEAUTYISTANBUL 2026, Nexvel Biotech actively introduced its medical aesthetics technologies and brand competitiveness to buyers across Europe, the Middle East, and Asia. During the exhibition, the company’s Aesthetic Medicines portfolio—including skin boosters and dermal fillers—received strong interest from overseas medical professionals and buyers, with positive evaluations focusing on product stability and differentiated formulation technologies. In particular, the company’s medical device-based technologies are now being applied to its recently launched cosmetic brand, generating positive market responses. Industry observers believe that this medically driven functional cosmetics approach aligns well with growing global consumer demand for products that combine efficacy, safety, and professional expertise. The global beauty market has recently seen rapid growth in the “cosmeceutical” sector, where consumers increasingly seek both skin improvement benefits and medical-grade reliability, further increasing the market influence of companies with medical technology expertise. Keeping pace with these trends, Nexvel Biotech is expanding the R&D capabilities and quality management systems established in the medical device sector into the cosmetics field. Industry insiders note that global markets are increasingly placing greater trust in companies that directly operate their own manufacturing infrastructure and quality control systems. They also emphasize that medical technology-based companies entering the cosmetics industry can gain strong advantages in both product reliability and premium brand positioning. At the same time, Nexvel Biotech is accelerating the expansion of its global distribution network. Beginning with the Istanbul exhibition, the company plans to continue participating in major international exhibitions across Europe, the Middle East, and Asia to strengthen overseas partnerships and export channels. Active consultations with buyers and distributors from various countries are already underway, and discussions regarding exclusive distribution agreements and long-term supply partnerships are reportedly progressing in several regions. A representative from Nexvel Biotech stated, “Based on our patented technologies, in-house production infrastructure, and global distribution capabilities, we plan to further strengthen our competitiveness in the medical aesthetics market. We aim to build sustainable growth in global markets by expanding not only our medical device business but also our technology-driven cosmetics sector.” Meanwhile, the global medical aesthetics and cosmeceutical markets continue to experience steady growth driven by increasing demand for skin health and anti-aging solutions. Industry experts expect Korean companies that successfully secure technological expertise, manufacturing competitiveness, and global distribution capabilities simultaneously to stand out even more prominently in overseas markets in the future.        

2026.05.07

[Nexvel Biotech] Accelerates Global Expansion at BEAUTYISTANBUL 2026

Nexvel Biotech Accelerates Global Expansion at BEAUTYISTANBUL 2026Advanced HA-Based Aesthetic Solutions Draw Attention from Global Buyers and Medical Professionals South Korean medical aesthetic company Nexvel Biotech is accelerating its expansion into overseas markets after participating in BEAUTYISTANBUL 2026, one of the largest beauty exhibitions serving as a strategic hub connecting Europe, Asia, and the Middle East. Recognized as a key international exhibition linking Europe, the Middle East, and CIS countries, BEAUTYISTANBUL brings together global beauty and aesthetic brands, medical professionals, distributors, and buyers. In recent years, the exhibition has also emerged as a major platform for competition in the medical aesthetics sector, particularly amid growing global demand for skin boosters and dermal fillers. At this year’s exhibition, Nexvel Biotech showcased its core Aesthetic Medicines portfolio, including Dual HA Skin Booster, Aeshilo, CE-certified Roseeplla Filler, and the Amethea Skin Booster series. According to industry sources, the company attracted strong interest from overseas medical professionals and distributors, particularly regarding product stability, differentiated formulations, and clinical suitability. Industry experts especially highlighted the company’s Dual HA-based skin booster technology. By combining high- and low-molecular-weight hyaluronic acid (HA), the formulation is designed to simultaneously enhance long-lasting hydration and skin elasticity. As the global medical aesthetics market increasingly shifts beyond simple volumizing procedures toward “skin quality” enhancement, this multifunctional approach is being viewed as a strong competitive advantage. The CE-certified Roseeplla Filler also drew attention for its potential competitiveness in the European market. CE certification is recognized as a key indicator that a product meets the safety and quality standards required for entry into Europe, making it an essential factor in global market expansion. Industry officials noted that international markets are increasingly prioritizing product safety and clinical reliability over price competitiveness alone, emphasizing the growing importance of advanced technology and global certifications for Korean aesthetic manufacturers. During the exhibition, Nexvel Biotech also engaged in active consultations with buyers from Europe, the Middle East, and Southeast Asia. Discussions regarding product supply partnerships and distribution agreements were particularly active in countries experiencing rapid growth in premium clinic-centered aesthetic markets, raising expectations for future expansion of the company’s global distributor network. A representative from Nexvel Biotech stated, “Through our participation in BEAUTYISTANBUL 2026, we were able to effectively introduce our technological capabilities and product competitiveness to the global market. We will continue strengthening our presence in the international medical aesthetics industry through ongoing R&D investment and the expansion of global certifications.” Meanwhile, the global medical aesthetics market continues to experience steady growth driven by rising demand for skin rejuvenation and anti-aging treatments. Skin boosters and dermal fillers are expected to remain among the key categories leading future market expansion, while industry attention is increasingly focused on how Korean companies’ technology-driven premium strategies will perform on the global stage.

2026.05.07